HomeCompareCNVT vs JNJ

CNVT vs JNJ: Dividend Comparison 2026

CNVT yields 5000000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNVT wins by $4.651129742658086e+43M in total portfolio value
10 years
CNVT
CNVT
● Live price
5000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.651129742658086e+43M
Annual income
$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00
Full CNVT calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CNVT vs JNJ

📍 CNVT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNVTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNVT + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNVT pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNVT
Annual income on $10K today (after 15% tax)
$425,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$39,533,047,462,834,250,000,000,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CNVT beats the other by $39,533,047,462,834,250,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNVT + JNJ for your $10,000?

CNVT: 50%JNJ: 50%
100% JNJ50/50100% CNVT
Portfolio after 10yr
$2.325564871329043e+43M
Annual income
$23,254,733,801,667,206,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CNVT
No analyst data
Altman Z
-13.9
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNVT buys
0
JNJ buys
0
No recent congressional trades found for CNVT or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNVTJNJ
Forward yield5000000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.651129742658086e+43M$30.3K
Annual income after 10y$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.651117771440442e+43M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CNVT vs JNJ ($10,000, DRIP)

YearCNVT PortfolioCNVT Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$500,010,700$500,000,000.00$10,592$272.30+$500.00MCNVT
2$23,365,520,992,757$23,364,985,981,308.41$11,289$357.73+$23365520.98MCNVT
3$1,020,442,548,175,215,100$1,020,417,547,067,752,800.00$12,123$472.89+$1020442548175.20MCNVT
4$41,650,346,151,752,480,000,000$41,649,254,278,225,940,000,000.00$13,141$629.86+$41650346151752480.00MCNVT
5$1,588,787,048,835,084,000,000,000,000$1,588,742,482,964,701,800,000,000,000.00$14,408$846.81+$1.588787048835084e+21MCNVT
6$56,640,860,400,245,200,000,000,000,000,000$56,639,160,398,102,940,000,000,000,000,000.00$16,021$1,151.60+$5.66408604002452e+25MCNVT
7$1,887,170,449,619,629,000,000,000,000,000,000,000$1,887,109,843,899,000,500,000,000,000,000,000,000.00$18,122$1,588.22+$1.887170449619629e+30MCNVT
8$58,763,764,792,023,670,000,000,000,000,000,000,000,000$58,761,745,519,642,570,000,000,000,000,000,000,000,000.00$20,930$2,228.20+$5.876376479202367e+34MCNVT
9$1,710,115,183,602,138,000,000,000,000,000,000,000,000,000,000$1,710,052,306,373,811,000,000,000,000,000,000,000,000,000,000.00$24,792$3,191.91+$1.710115183602138e+39MCNVT
10$46,511,297,426,580,864,000,000,000,000,000,000,000,000,000,000,000$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$4.651129742658086e+43MCNVT

CNVT vs JNJ: Complete Analysis 2026

CNVTStock

CVF Technologies Corporation engages in the investment, development, and management of early stage private companies that operate in the environmental technology sector in the United States and Canada. The company, through its interests in Xylodyne Corporation, develops proprietary technology relating to electric vehicles. CVF Technologies, through its subsidiary, Ecoval Corporation, involves in the development, manufacture, and marketing of organic herbicides, insecticides, and tree recovery systems primarily for the lawn and garden retail/consumer market, and specialty agricultural markets. The company, through its other subsidiary, G.P. Royalty Distribution Corporation, provides products and services to the jewelry industry to enable diamonds and other precious gems to be uniquely identified non-invasively using a patented low power laser imaging system. CVF Technologies was founded in 1989 and is based in Williamsville, New York.

Full CNVT Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CNVT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNVT vs SCHDCNVT vs JEPICNVT vs OCNVT vs KOCNVT vs MAINCNVT vs ABBVCNVT vs MRKCNVT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.